Inhaltsbereich
| 7 Einträge |
Seite 1 / 1
 Druckansicht
|
| Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. |
| Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O'Byrne KJ, Gatzemeier U |
| Lung cancer (Amsterdam, Netherlands). 2012 Apr 11. pii: S0169-5002(12)00121-3. doi: 10.1016/j.lungcan.2012.03.010 |
| PMID: 22498112 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. |
| Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U |
| Lancet (London, England). 2009 May 4. pii: S0140-6736(09)60569-9. doi: 10.1016/S0140-6736(09)60569-9 |
| PMID: 19410716 |
| Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. |
| Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jul 25. pii: JCO.2016.67.6601. doi: 10.1200/JCO.2016.67.6601 |
| PMID: 27458307 |
| FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). |
| Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, Gatzemeier U, Bajeta E, Emig M, Pereira JR |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jan 1. pii: 10.1200/jco.2008.26.15_suppl.3 |
| PMID: 27948496 |
| Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX). |
| Von Pawel J, Park K, Pereira JR, Szczesna A, Yu C, Ganul VL, Krzakowski M, Roh JK, Pilz K, Pirker R |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Jan 1. pii: 10.1200/jco.2006.24.18_suppl.7109 |
| PMID: 27953547 |
| Prognostic factors in advanced NSCLC: Experience from the FLEX trial. |
| Pirker R, Rodrigues-Pereira J, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Emig M, Gatzemeier U |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 1. pii: 10.1200/jco.2009.27.15_suppl.8083 |
| PMID: 27962658 |
| First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. |
| Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV |
| The New England journal of medicine. 2018 Sep 25. doi: 10.1056/NEJMoa1809064 |
| PMID: 30280641 |
| 7 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
